Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano announced that Chief Executive Officer Vuong Trieu will present the Deciparticle nanomedicine platform at the BIO International Convention 2026 in San Diego. The presentation will highlight the development of ultra-small nanomedicine formulations designed to enable intravenous administration of highly water-insoluble therapeutics, a significant challenge in drug delivery.
The Deciparticle platform utilizes proprietary amphiphilic polymer systems capable of forming sub-20 nanometer particles for oncology and other therapeutic applications. This technology could potentially improve the therapeutic index of existing drugs and unlock new clinical potential for both established and novel therapeutics.
The companies plan to showcase development progress across multiple Deciparticle programs, including Sapu006, a polysorbate-free intravenous docetaxel formulation moving into Phase 1b clinical evaluation, and Sapu003, an intravenous everolimus nanomedicine program currently in a global Phase 1b clinical trial. These programs address key limitations of current formulations, such as the use of toxic excipients like polysorbate.
The presentation will also highlight the integration of artificial intelligence and knowledge-organization technologies into formulation development and translational oncology workflows through the PDAOAI platform. This AI-enabled platform supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, aiming to address high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents.
Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical potential. The Deciparticle platform represents a significant advancement in nanomedicine, potentially enabling the intravenous use of drugs that are currently limited by poor water solubility.
The BIO International Convention is a premier global event for the biotechnology industry, and this presentation underscores the importance of innovative drug delivery technologies in addressing critical medical needs. The ability to intravenously administer water-insoluble therapeutics could expand treatment options for cancer and other diseases, potentially improving patient outcomes and quality of life.
For more information, visit the full press release at https://ibn.fm/RUG7m.
